Lineage Cell Therapeutics, Inc. Earnings Per Share Diluted

Quick Answer

Lineage Cell Therapeutics, Inc. reported Earnings Per Share Diluted of $0.28 (loss) per share for the year ending 2025.

  • Lineage Cell Therapeutics, Inc. showed a decrease of -211.1% in Earnings Per Share Diluted from 2024 to 2025.
  • This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
  • XBRL data for this metric is available from 2014 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2014 to 2025), Lineage Cell Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 49.1%.
  • Historical annual values: Fiscal year 2025: $0.28 (loss) per share | Fiscal year 2024: $0.09 (loss) per share | Fiscal year 2023: $0.12 (loss) per share | Fiscal year 2022: $0.15 (loss) per share | Fiscal year 2017: $0.17 (loss) per share | Fiscal year 2016: $0.34 per share | Fiscal year 2015: $0.59 (loss) per share | Fiscal year 2014: $0.55 (loss) per share.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: